Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YT-E001
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
YT-E001 is an autologous T-cell receptor-engineered T-cell (TCR-T) therapy developed by Fujian Cancer Hospital for the treatment of Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC). The therapy involves the lentiviral transduction of a patient's own T cells with high-affinity TCRs specifically screened to recognize EBV antigens commonly expressed in NPC cells, including Latent Membrane Protein 1 (LMP1), Latent Membrane Protein 2 (LMP2), and Epstein-Barr Nuclear Antigen 1 (EBNA1). By targeting these viral proteins, YT-E001 aims to selectively identify and eliminate EBV-infected malignant cells. It is currently being evaluated in Phase I/II clinical trials for patients with relapsed or progressive NPC who have failed prior therapies, typically following a lymphodepletion regimen of cyclophosphamide and fludarabine.
- Other names
- EBV-TCR-TEBV-TCR-T (YT-E001)
02
Targets
HLA-A*02:01-restricted Epstein-Barr virus latent membrane protein 1/2 and nuclear antigen 1 peptide-MHC complexesHLA-A*24:02-EBV-pMHC (HLA-A*24:02-restricted Epstein-Barr virus latent membrane protein 1/2 and nuclear antigen 1 peptide-major histocompatibility complexes)
Beyond the preview
Go deeper on YT-E001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YT-E001.